By stimulating the body’s natural immune system, immunotherapy mobilizes the body’s own powerful anticancer mechanisms to help achieve a durable response.

Video guide for patients


Learn more by watching Immunotherapy for Cancer: A Guide for Patients (3:26)
This animated video explains the 
benefits of immunotherapy to cancer patients.

Side Effects


Cancer immunotherapy activates T cells and B cells that target specific tumor antigens


The activated immune system is primed to recognize tumor antigens expressed by each patient’s unique and frequently changing population of cancer cells1

Some activated T cells kill tumor cells directly or indirectly1

Some activated T cells activate B cells, which become antibody-producing plasma cells1


Learn more by watching Immunotherapy Is Tumor-Specific (2:03)


Cancer immunotherapy treatment is designed to support the immune system’s ability to adapt its attack over time

Each patient’s population of tumor cells mutates over time, which may result in resistance to traditional
anticancer therapies1

When a tumor cell is killed, additional antigens are released, stimulating activation of new populations of
T cells and B cells that recognize tumor antigens1,2,4,5

This can result in an expanding cascade of immune cells that is able to recognize cancer cells bearing a variety of tumor antigens as the tumor mutates over time3-6


Learn more by watching Immunotherapy Is Designed to Support Immune System Adaptability(2:42)



Immunotherapy for cancer stimulates immunologic memory, which may lead to a prolonged anti-tumor response


Some activated immune cells become memory cells, which remain primed to stimulate an anticancer immune response when tumor cells bearing target antigens are encountered within the body1,7,8


Learn more by watching Immunotherapy Empowers a Durable Immune Response (2:19)


  1. Murphy K, Travers P, Walport M, eds. Janeway’s Immunobiology. 7th ed. Garland Science, Taylor & Frances Group, LLC. New York, NY: 2008.
  2. Namm JP, Li Q, Lao X, et al. J Surg Oncol. 2012;105(4):431-435.
  3. Sharma P, Wagner K, Wolchok JD, Allison JP. Nat Rev Cancer. 2011;11(11):805-812.
  4. Ribas A, Butterfield LH, Glaspy JA, Economou JS. J Clin Oncol. 2003;21(12):2415-2432.
  5. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. CA Cancer J Clin. 2012;62(5):309-335.
  6. Disis ML, Strickler JH, Wallace D, et al. J Clin Oncol. 2008;26(suppl):(May 20 suppl; abstr 3015).
  7. Klebanoff CA, Gattinoni L, Restifo NP. Immunol Rev. 2006;211:214-224.
  8. Mullins DW, Sheasley SL, Ream RM, Bullock TNJ, Fu Y-X, Engelhard VH. J Exp Med. 2003;198(7):1023-1034.